Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.57 |
| ▸ | ADORA2B | P29275 | 7/20 | 0.56 |
| ▸ | ADORA2A | P29274 | 6/20 | 0.56 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.52 |
| ▸ | NOS2 | P35228 | 1/20 | 0.48 |
| ▸ | MMP13 | P45452 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2085129 | 0.83 | ADORA2A (0.52) | ADORA2BADORA2AADORA3L3MBTL1 | |
| SCHEMBL13991764 | 0.83 | GPR119 (0.53) | GPR119ADORA2BADORA2AADORA3ALDH1A1 | |
| SCHEMBL4914447 | 0.83 | GPR119 (0.53) | GPR119ADORA2BADORA2AADORA3ALDH1A1 | |
| SCHEMBL1328780 | 0.81 | GPR119 (0.60) | GPR119ADORA2BADORA2AUSP30MMP13 | |
| SCHEMBL25221384 | 0.81 | GPR119 (0.53) | GPR119ADORA2BADORA2AADORA3ALDH1A1 | |
| SCHEMBL9933572 | 0.81 | GPR119 (0.53) | GPR119ADORA2BADORA2AADORA3ALDH1A1 | |
| SCHEMBL209901 | 0.81 | GPR119 (0.53) | GPR119ADORA2BADORA2AADORA3ALDH1A1 | |
| SCHEMBL1087667 | 0.81 | NOS2 (0.72) | GPR119ALDH1A1NPC1MAPTMAPK1 | |
| SCHEMBL12125611 | 0.79 | GPR119 (0.54) | GPR119ADORA2BADORA2AADORA3ALDH1A1 | |
| SCHEMBL12128388 | 0.79 | GPR119 (0.56) | GPR119ADORA2BADORA2AADORA3USP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1613613-B1 | CXCR4 CHEMOKINE RECEPTOR BINDING COMPOUNDS | GENZYME CORP (US) | 2021-06-02 | — | — | EP | disclosed |
| US-7863293-B2 | CXCR4 chemokine receptor binding compounds | GENZYME CORPORATION (US) | 2011-01-04 | — | — | US | disclosed |
| US-20080255197-A1 | CXCR4 CHEMOKINE RECEPTOR BINDING COMPOUNDS | ANORMED CORPORATION (CA) | 2008-10-16 | — | — | US | disclosed |
| US-7291631-B2 | CXCR4 chemokine receptor binding compounds | GENZYME CORPORATION (US) | 2007-11-06 | — | — | US | disclosed |
| US-20040209921-A1 | CXCR4 chemokine receptor binding comounds | ANORMED CORPORATION (CA) | 2004-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040209921-A1 | CXCR4 chemokine receptor binding comounds | CXCR4, CXCR1, CXCR3 | GPR119 294/4885ADORA2B 144/4885ADORA2A 66/4885 |
| US-20080255197-A1 | CXCR4 CHEMOKINE RECEPTOR BINDING COMPOUNDS | CXCR4, CXCR1, CXCR3 | GPR119 159/4885ADORA2B 148/4885ADORA2A 58/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.